In NEJM: Dose Escalation Best Approach for Sickle Cell Med in Africa
Post Date: June 25, 2020 | Publish Date: June 25, 2020
“The study shows clearly that the optimized dosing strategy for hydroxyurea, though it requires more effort than a fixed-dose treatment regimen, results in far better outcomes for children with sickle cell anemia,”
— Russell Ware, MD, PhD
Read the media release about the NOHARM MTD study
Publication Information
| Original title: | Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa |
| Published in: | New England Journal of Medicine |
| Publish date: | June 25, 2020 |
